Opendata, web and dolomites

TIR-C SIGNED

NEXT GENERATION TOPICAL MEDICATION TO TREAT IMMUNE RESPONSES IN ATOPIC DERMATITIS – THE MOST COMMON CAUSE OF ECZEMA

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TIR-C project word cloud

Explore the words cloud of the TIR-C project. It provides you a very rough idea of what is the project "TIR-C" about.

safe    communicated    cro    affordable    ab    health    local    patients    group    societies    children    conduct    deprivation    escalation    plan    therapy    burden    contract    unmet    clinical    infected    tirmed    anti    contain    dermatology    manufacturing    damage    80    excellent    extremely    consistently    mild    costly    relives    confirm    interfere    topical    readiness    itch    market    survey    iia    expenditures    freedom    symptoms    eliminate    trials    inflammation    mechanism    formulation    approvals    economic    moderate    consequently    ad    operate    sleep    unsuitable    regulatory    rate    entirely    sufferers    life    lesions    water    intravenously    biologics    steroid    commercialisation    defences    self    feasibility    diabetes    poses    productivity    profile    disease    prevent    skin    severe    quality    kols    patient    vital    works    validate    psychological    symptom    steroids    blockbuster    pricing    drafted    tir    cream    treatment    clinicians    safety    pharma    dermatitis    preparations    administrated    atopic    mind    action    enormous    unresolved    immune    persons   

Project "TIR-C" data sheet

The following table provides information about the project.

Coordinator
TIRMED PHARMA AB 

Organization address
address: SPETS ALVIKSVAGEN 1
city: BROMMA
postcode: 16753
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TIRMED PHARMA AB SE (BROMMA) coordinator 50˙000.00

Map

 Project objective

TIRmed pharma AB has developed a non-steroid cream that relives itch in Atopic Dermatitis (AD). Itch is an enormous, unresolved symptom in AD, induced by inflammation and skin damage. AD poses a significant burden on societies and patients’ quality of life due to itch, infected lesions, sleep deprivation, and consequently productivity loss, psychological health and treatment-associated expenditures. Persons affected by AD consistently rate AD management to be comparable to diabetes management. Our TIR-C cream doesn’t contain steroids and works through an entirely novel mechanism of action. The therapy has been developed with the largest patient group in mind; children. TIR-C has the potential to become a blockbuster in AD management as it has an excellent safety profile, is very affordable, is easy to self-apply (water-based), doesn’t interfere with vital immune defences and has the potential to prevent disease escalation. We target mild-to-moderate symptoms (80% of all AD sufferers), aiming to eliminate the need for intravenously administrated biologics. Biologics are not only extremely costly, but also associated with severe side effects, making them unsuitable for children. The unmet need for safe, topical anti-itch-treatment in persons with mild-to-moderate AD has been clearly communicated by leading contract research organizations, KOLs and clinicians within dermatology. TIR-C is at Technology Readiness Level 4 with established manufacturing and formulation processes and a clinical development plan drafted in collaboration with a leading CRO in dermatology. The proposed feasibility study will advance preparations for commercialisation by allowing us to confirm regulatory requirements needed for market approvals, validate pricing through a health-economic survey in the EU, identify a local CRO to conduct the planned phase I/IIa clinical trials and confirm Freedom to Operate.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TIR-C" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TIR-C" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

CodeAll (2019)

The development of an innovative toolkit for learning programming with the use of the Internet of Things sensors and actuators

Read More  

HAC (2019)

ADVANCED TREATMENT OF CONTAMINATED SOIL

Read More  

ClosedToe (2020)

Sock toe closing system for circular knitting machines

Read More